Robert C. Doebele, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz

Robert C. Doebele, University of Colorado Anschutz Medical Campus

Caption

Robert C. Doebele, MD, PhD, and colleagues show that the prodrug tarloxotinib is active against NRG1-fusion cancers no matter where the cancer lives in the body.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.